Management of prostate cancer patients with lymph node involvement: A rapidly evolving paradigm

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 956-967

  Créhange, Gilles ^a,b   Chen, Chien Peter ^a   Hsu, Charles C ^a   Kased, Norbert ^a   Coakley, Fergus V ^a   Kurhanewicz, John ^a   Roach, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Fluorocholine PET CT imaging; IGRT; IMRT; Lymph node metastasis; MR lymphangiography; Prostate cancer; Sentinel node; SPECT CT imaging

Indexed keywords

16 BETA FLUORO 5 DIHYDROTESTOSTERONE F 18; ANTI 1AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID F 18; CAPROMAB PENDETIDE IN 111; CARBON 11; CHOLINE; CHOLINE C 11; FERUMOXTRAN-10; FERUMOXYTOL; FLUORINE 18; FLUORINE CHOLINE; GLUTARIC ACID; IODINE 123; IOFOLASTAT I 123; MIP 1072 I 123; MIP 1095 I 123; N N ((S) 1,3 DICARBOXYPROPYL) 4 FLUOROBENZYL L CYSTEINE F 18; NANOPARTICLE; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; ISOTOPE LABELING; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCULT CANCER; ONCOLOGY; PELVIS LYMPH NODE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK BENEFIT ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS;

EID: 84867143264     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.005     Document Type: Review

References (110)

1. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523.
2. Rubin M.A.L.M. Prostate cancer: molecular pathology and biologic determinants. Comprehensive textbook of genitourinary oncology 2005, Lippincott Williams & Wilkins, Philadelphia, PA. N.J.S.P. Vogelzang, W.U. Shipley, F.M. Debruyne (Eds.).
3. Stephenson A.J., Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005, 23:8198-8203.
4. Trapasso J.G., deKernion J.B., Smith R.B., Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994, 152:1821-1825.
5. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876-881.
6. Briganti A., Blute M.L., Eastham J.H., et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009, 55:1251-1265.
7. Briganti A., Capitanio U., Chun F.K., et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008, 54:794-802.
8. Swanson G.P., Thompson I.M., Basler J. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 2006, 107:439-450.
9. Swanson G.P., Thompson I.M., Basler J. Treatment options in lymph node-positive prostate cancer. Cancer 2006, 106:2531-2539.
10. Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999, 17:1499-1507.
11. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007, 69:1095-1101.
12. Nguyen P.L., Chen M.H., Hoffman K.E., Katz M.S., D'Amico A.V. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 2009, 74:104-109.
13. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:110-114.
14. Roach M. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:1923-1924.
15. Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002, 167:1681-1686.
16. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol 2003, 21:245-254.
17. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
18. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., Studer U.E. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?. Eur Urol 2006, 50:272-279.
19. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007, 178:864-870. (discussion 70-1).
20. Bader P., Burkhard F.C., Markwalder R., Studer U.E. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol 2002, 168:514-518. (discussion 8).
21. Mattei A., Fuechsel F.G., Bhatta Dhar N., et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008, 53:118-125.
22. Wawroschek F., Vogt H., Weckermann D., Wagner T., Hamm M., Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001, 166:1715-1719.
23. Joslyn S.A., Konety B.R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006, 68:121-125.
24. Borley N., Fabrin K., Sriprasad S., et al. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in " high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol 2003, 37:382-386.
25. Wolf J.S., Cher M., Dall'era M., Presti J.C., Hricak H., Carroll P.R. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995, 153:993-999.
26. Hricak H., Dooms G.C., Jeffrey R.B., et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987, 162:331-336.
27. Jager G.J., Ruijter E.T., van de Kaa C.A., et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996, 166:845-852.
28. Oyen R.H., Van Poppel H.P., Ameye F.E., Van de Voorde W.A., Baert A.L., Baert L.V. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994, 190:315-322.
29. Abuzallouf S., Dayes I., Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004, 171:2122-2127.
30. Tiguert R., Gheiler E.L., Tefilli M.V., et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999, 53:367-371.
31. DeWyngaert J.K., Noz M.E., Ellerin B., Kramer E.L., Maguire G.Q., Zeleznik M.P. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 2004, 60:654-662.
32. Han M., Partin A.W. Current clinical applications of the In-capromab pendetide scan (ProstaScint(R) Scan, Cyt-356). Rev Urol 2001, 3:165-171.
33. Sodee D.B., Nelson A.D., Faulhaber P.F., Maclennan G.T., Resnick M.I., Bakale G. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer 2005, 3:230-238.
34. Taneja S.S. ProstaScint(R) scan: contemporary use in clinical practice. Rev Urol 2004, 6(Suppl 10):S19-28.
35. Ponsky L.E., Cherullo E.E., Starkey R., Nelson D., Neumann D., Zippe C.D. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002, 5:132-135.
36. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003, 21:1715-1721.
37. Bander N.H. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006, 3:216-225.
38. Nagda S.N., Mohideen N., Lo S.S., et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67:834-840.
39. Heesakkers R.A., Hovels A.M., Jager G.J., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9:850-856.
40. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
41. Ross R., Harisinghani M. New clinical imaging modalities in prostate cancer. Hematol Oncol Clin North Am 2006, 20:811-830.
42. *-weighted MR Imaging at 1.5 and 3.0 T: early experience. Radiology 2006, 239:481-487.
43. Harisinghani M.G., Saksena M.A., Hahn P.F., et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?. AJR Am J Roentgenol 2006, 186:144-148.
44. Shih H.A., Harisinghani M., Zietman A.L., Wolfgang J.A., Saksena M., Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 2005, 63:1262-1269.
45. Harisinghani M., Ross R.W., Guimaraes A.R., Weissleder R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 2007, 9:1160-1165.
46. Fox J.J., Morris M.J., Larson S.M., Schoder H., Scher H.I. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011, 50(Suppl 1):39-48.
47. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011, 52:81-89.
48. Breeuwsma A.J., Pruim J., van den Bergh A.C., et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010, 77:160-164.
49. Giovacchini G, Picchio M, Coradeschi E, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging; 37:301-9.
50. Giovacchini G., Picchio M., Coradeschi E., et al. [(11) C] choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008, 35:1065-1073.
51. Kwee S.A., Coel M.N., Lim J., Ko J.P. Prostate cancer localization with 18 fluorine fluorocholine positron emission tomography. J Urol 2005, 173:252-255.
52. Martorana G., Schiavina R., Corti B., et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006, 176:954-960. (discussion 60).
53. Oehr P., Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol 2007, 19:259-264.
54. Picchio M., Messa C., Landoni C., et al. Value of [11C] choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003, 169:1337-1340.
55. Reske S.N., Blumstein N.M., Neumaier B., et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006, 47:1249-1254.
56. Schiavina R., Scattoni V., Castellucci P., et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008, 54:392-401.
57. Sutinen E., Nurmi M., Roivainen A., et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004, 31:317-324.
58. Winter A., Uphoff J., Henke R.P., Wawroschek F. First Results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010, 84:418-423.
59. Igerc I., Kohlfurst S., Gallowitsch H.J., et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:976-983.
60. Albrecht S., Buchegger F., Soloviev D., et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007, 34:185-196.
61. Cimitan M., Bortolus R., Morassut S., et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33:1387-1398.
62. Oyama N., Miller T.R., Dehdashti F., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003, 44:549-555.
63. Schmid D.T., John H., Zweifel R., et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005, 235:623-628.
64. Wachter S., Tomek S., Kurtaran A., et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006, 24:2513-2519.
65. de Jong I.J., Pruim J., Elsinga P.H., Vaalburg W., Mensink H.J. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003, 44:331-335.
66. Hacker A., Jeschke S., Leeb K., et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006, 176:2014-2018. (discussion 8-9).
67. Husarik D.B., Miralbell R., Dubs M., et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263.
68. Beheshti M., Imamovic L., Broinger G., et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010, 254:925-933.
69. Krause B.J., Souvatzoglou M., Tuncel M., et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:18-23.
70. Rinnab L., Simon J., Hautmann R.E., et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009, 27:619-625.
71. Castellucci P., Fuccio C., Nanni C., et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009, 50:1394-1400.
72. Mease R.C., Dusich C.L., Foss C.A., et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008, 14:3036-3043.
73. Fox J.J., Autran-Blanc E., Morris M.J., et al. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med 2011, 52:1727-1732.
74. Schuster D.M., Savir-Baruch B., Nieh P.T., et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 2011, 259:852-861.
75. Ganswindt U., Paulsen F., Corvin S., et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 2005, 5:91.
76. Ganswindt U., Paulsen F., Corvin S., et al. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 2007, 67:347-355.
77. Takashima H., Egawa M., Imao T., Fukuda M., Yokoyama K., Namiki M. Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 2004, 171:2268-2271.
78. Wawroschek F., Vogt H., Weckermann D., Wagner T., Harzmann R. The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification. Eur Urol 1999, 36:595-600.
79. Weckermann D., Dorn R., Trefz M., Wagner T., Wawroschek F., Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients. J Urol 2007, 177:916-920.
80. Wawroschek F., Vogt H., Wengenmair H., et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003, 70:303-310.
81. Wawroschek F., Wagner T., Hamm M., et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003, 43:132-136. (discussion 7).
82. Weckermann D., Wawroschek F., Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?. Eur Urol 2005, 47:45-50. (discussion-1).
83. Vermeeren L., Meinhardt W., van der Poel H.G. Valdes Olmos RA. Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer. Eur J Nucl Med Mol Imaging 2010, 37:2021-2026.
84. Krengli M., Ballare A., Cannillo B., et al. Potential advantage of studying the lymphatic drainage by sentinel node technique and SPECT-CT image fusion for pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:1100-1104.
85. Gronau E.W.D., Harzmann R. Sentinel lymph node resection in prostate cancer patients with PSA higher than 20ng/ml. XXth Congress of the European Association of Urology 2005:67, Eur Urol, Istanbul, Turkey.
86. Maresca K.P., Hillier S.M., Femia F.J., et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009, 52:347-357.
87. Hillier S.M., Maresca K.P., Femia F.J., et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009, 69:6932-6940.
88. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
89. Pilepich M.V., Krall J.M., Sause W.T., et al. Prognostic factors in carcinoma of the prostate-analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987, 13:339-349.
90. Hanks G.E., Buzydlowski J., Sause W.T., et al. Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 1998, 40:765-768.
91. Sands M.E., Pollack A., Zagars G.K. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 1995, 31:13-19.
92. Whittington R., Malkowicz B., Barnes M.M., et al. Combined hormonal and radiation therapy for lymph node-positive prostate cancer. Urology 1995, 46:213-219.
93. Wiegel T., Bressel M. Stage D1 prostate cancer-is radiotherapy and early hormonal therapy equivalent to radical prostatectomy, radiotherapy, and early hormonal therapy? regarding Sands et al., IJROBP 31:13-19; 1995. Int J Radiat Oncol Biol Phys 1995, 32:896-897.
94. Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005, 23:800-807.
95. Da Pozzo L.F., Cozzarini C., Briganti A., et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009, 55:1003-1011.
96. Iversen P., Roder M.A. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther 2008, 8:361-369.
97. Jereczek-Fossa B.A., Fariselli L., Beltramo G., et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 2009, 93:14-17.
98. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
99. Wang-Chesebro A., Xia P., Coleman J., Akazawa C., Roach M. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:654-662.
100. Guerrero Urbano T, Khoo V, Staffurth J, et al. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol) 2010;22:236-244.
101. Engels B., Soete G., Tournel K., et al. Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat 2009, 8:353-359.
102. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:11-18.
103. Fonteyne V., De Gersem W., De Neve W., et al. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:1013-1020.
104. Hong T.S., Tome W.A., Jaradat H., Raisbeck B.M., Ritter M.A. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncol 2006, 45:717-727.
105. McCammon R., Rusthoven K.E., Kavanagh B., Newell S., Newman F., Raben D. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:413-420.
106. Xia P., Qi P., Hwang A., Kinsey E., Pouliot J., Roach M. Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes. Med Phys 2010, 37:5006-5013.
107. Ludlum E., Mu G., Weinberg V., Roach M., Verhey L.J., Xia P. An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys 2007, 34:4750-4756.
108. Mottet N., Peneau M., Mazeron J., Molinie V., Richaud P. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. 2010 ASCO Annual Meeting 2010, J Clin Oncol, Chicago Convention Center, (p. 15s).
109. Warde P, Mason, MD, Sydes, MR, Gospodarowicz, MK, Swanson, GP, Kirkbride, E, Kostashuk, E, Hetherington, J, Ding, K, Parulekar, W, NCIC CTG PR.3 / MRC PR07 / SWOG JPR3 Investigators. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advancedprostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT 00002633). In: 2010 ASCO Annual Meeting; 2010; Chicago Convention Center: J Clin Oncol; 2010 (p. 18s).
110. Ganswindt U., Schilling D., Muller A.C., Bares R., Bartenstein P., Belka C. Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys 2011, 79:1364-1372.